CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
Letrozoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03747042
NCT03747042Phase 2Completed
CompareCT.gov

Pre-Surgical Trial of Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

University of Texas Southwestern Medical Center·interventional·Posted Nov 20, 2018·Updated Mar 16, 2026

In Brief

A Phase 2 clinical trial evaluating Letrozole for Breast Cancer Female. Completed, enrolled 61 participants across 1 site.

Detailed Summary

A short pre-surgical non-therapeutic trial involving postmenopausal women with newly diagnosed eR+, HeR2-negative operable breast cancers. After undergoing a core needle biopsy for tissue acquisition, study participants will take a 7- to 30-day (1-4 weeks) course of letrozole in accordance with standard of care. They will then undergo definitive surgical resection of their primary tumor (mastectomy vs lumpectomy) as per standard of care guidelines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer Female
CountriesUnited States
CollaboratorsCancer Prevention Research Institute of Texas

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 20, 2018
Enrollment StartNov 27, 2018
Primary CompletionFeb 24, 2025
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 7.6 years ago

Interventions

Letrozoledrug

Patients will receive a prescription for letrozole to be taken orally for 7-30 days to allow for variations in surgical scheduling. Patients are to undergo surgical resection of their tumor the day after the last dose of letrozole. Post-treatment tumor biopsies (a goal of 4-6 cores) will be obtained following 7-56 days of letrozole treatment on the day of surgery.